[Symposium "Emerging Approaches to Cardiovascular Diseases: Detailed results and implications of the HOPE Study". Atlanta, 10. November 1999].
Bischoff
A
A
Aventis Pharma, Deutschland GmbH, Bad Soden.
D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D016757:Death, Sudden, Cardiac / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000517:prevention & control*; D017257:Ramipril / Q000494:pharmacology / Q000627:therapeutic use*; D020521:Stroke / Q000517:prevention & control*; D016019:Survival Analysis; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000150:complications / Q000188:drug therapy* / Q000209:etiology
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D017257:Ramipril